Is Thymosin Alpha-1 Legal in Texas? FDA and Compounding Status
HealthRX.com
Thymosin alpha-1 has no Texas-specific rule cited here
Key numbers
- 4 yes and 17 noFDA advisory committee vote on compounding thymosin alpha-1 in its free base and acetate formsSource: fda.gov, as cited Nov 8, 2026
- 1.6 mgDose per injection in the Italian Zadaxin label, not a US-approved doseSource: fda.gov, as cited Nov 8, 2026
- 4 weeksLength of the first dosing course in the Italian Zadaxin label, not a US-approved regimenSource: fda.gov, as cited Nov 8, 2026
At a glance
- FDA approval / None in the US; four orphan drug designations, which are not approvals [1]
- FDA list, state-licensed pharmacies / In none of the three categories [2]
- FDA list, outsourcing facilities / Category 3, nominated without adequate support [3]
- Advisory committee vote, December 4 2024 / 4 yes, 17 no, no abstentions, on both forms [4]
- HHS October 2026 peptide draft policy / Not among the six named peptides [5]
- Approved as a medicine elsewhere / Italy, India and Hong Kong, per FDA [1]
- WADA 2026 Prohibited List / Not named [6]
Is thymosin alpha-1 FDA-approved?
No. A Drugs@FDA search found no US application for it. It holds four US orphan drug designations, which come from a separate process and are not an approval [1].
It is approved as a medicine in some other countries. FDA's December 2024 review lists Italy, where Zadaxin is authorized as an adjuvant to influenza vaccination in immunocompromised people; India, for chronic hepatitis B in adults 18 and older with compensated liver disease and virus replication; and Hong Kong [1]. The European Medicines Agency holds only an orphan designation for hepatocellular carcinoma, not a marketing approval [1].
What has FDA said about compounding it?
FDA's list for state-licensed pharmacies and physicians, updated May 14, 2026, places thymosin alpha-1 in none of its three categories. The category 1 policy, under which FDA generally takes no action against compounders that meet its conditions, does not apply to it [2]. On the separate list for outsourcing facilities, updated March 21, 2025, it is category 3, 'nominated without adequate support' [3].
FDA's page on bulk substances that may present significant safety risks lists it in the 'nominated but withdrawn' table. It had been in category 2 and came off when the nominators withdrew. FDA's concerns remain posted: significant risk of immunogenicity for certain routes of administration, peptide-impurity and characterization problems, and safety information 'inadequate for the agency to sufficiently understand the extent of any safety issues' [7].
On December 4, 2024, FDA's Pharmacy Compounding Advisory Committee voted 4 yes and 17 no, with no abstentions, on both the free base and the acetate form. Members who voted no cited no compelling evidence of clinical effectiveness and safety [4]. FDA proposed that it not be added to the pharmacy bulks list [4]. It is also not among the six peptides in HHS's October 2026 draft enforcement-discretion policy [5].
What about Texas?
The FDA documents above are federal. They do not address Texas law, and no Texas statute or State Board of Pharmacy rule on thymosin alpha-1 is cited on this page. What is documented here is the federal position [1][2][3].
Questions worth asking
Is there an approved dose?
No US-approved dose exists [1]. The Italian Zadaxin label describes 1.6 mg of powder given subcutaneously or intramuscularly twice weekly for 4 weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That label says not for children, contraindicated in pregnancy and breastfeeding, caution in people with allergies or autoimmune disease, and caution with other immune-modulating drugs [1].
What is known about side effects?
FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [1]. Authors tied to the manufacturer report more than 4,400 people enrolled in trials and over 17 million doses of Zadaxin given after marketing, with adverse experiences 'infrequent and mild'. This is company-linked data [1].
A 2026 Cochrane review of 10 randomized trials in 1,349 adults with chronic hepatitis B found it may have caused fewer serious adverse events than the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence). The reviewers said they were not sure it helps [8].
Check what you know
Question 1 of 5
Score: 0 right, 0 of 5 answered
Frequently asked questions
Is thymosin alpha-1 legal in Texas?
Can a US pharmacy compound thymosin alpha-1?
Is thymosin alpha-1 approved anywhere?
Is thymosin alpha-1 banned in sport?
References
Show all 8 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- World Anti-Doping Agency.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026.